产品说明书

Halofuginone

Print
Chemical Structure| 55837-20-2 同义名 : 卤夫酮 ;RU-19110
CAS号 : 55837-20-2
货号 : A162412
分子式 : C16H17BrClN3O3
纯度 : 99%+
分子量 : 414.682
MDL号 : MFCD09834143
存储条件：

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 18 mg/mL(43.41 mM)，配合低频超声，并调节pH至5，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • tRNA synthetase

    prolyl-tRNA synthetase, Ki:18.3nM
描述 Halofuginone is the competitively inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/mL in mammal.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01978366 Duchenne Muscular Dystrophy Phase 2 Terminated(Dosing stopped) - United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT01847573 Duchenne Muscular Dystrophy Phase 1 Phase 2 Terminated(Dosing stopped) - United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT02525302 Duchenne Muscular Dystrophy Phase 2 Terminated(Dosing stopped) - United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.06mL

2.41mL

1.21mL

24.11mL

4.82mL

2.41mL
参考文献

[1]Nelson EF, Huang CW, et al. Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis. 2012;18:479-87.

[2]Keller TL, Zocco D, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.